Navigation Links
Adeona Appoints George A. Eby to Scientific Advisory Board

ANN ARBOR, Mich., Aug. 25, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN) announced today that it has appointed George A. Eby, a researcher who has conducted multiple clinical studies of zinc lozenges for the common cold, as a member of its Scientific Advisory Board.

Mr. Eby is a pioneer in the development of zinc lozenges as a treatment for the common cold. He has devoted more than 30 years to the study of zinc and is the executive director of the George Eby Research Institute. He was the first researcher to demonstrate with statistical significance that zinc lozenges can reduce the average duration of symptoms of the common cold by approximately seven days. Mr. Eby's groundbreaking placebo-controlled, randomized, double-blind clinical study was published in the January 1984 volume of American Society for Microbiology and is available at: His zinc studies have been cited in several journals, most recently in the "Zinc for the Common Cold Review" prepared by The Cochrane Collaboration® and "Zinc Lozenges May Shorten the Duration of Colds: A Systematic Review" in The Open Respiratory Medicine Journal, both published during 2011.

"I am pleased to join Adeona's Scientific Advisory Board," said George Eby. "Adeona's zinc acetate lozenges have the potential to reduce the duration and severity of the common cold for most people. Through the development of its family of zinc-based product candidates, Adeona is uniquely positioned to introduce this new zinc lozenge for the common cold into the marketplace. I look forward to using my 30 years of zinc lozenge research to guide Adeona as it takes advantage of this large market opportunity. It is reported that consumers in the U.S. spend approximately $2.9 billion annually on over-the-counter treatments for the common cold, most of which I deem ineffective beyond modest symptomatic relief."

James S. Kuo, M.D., M.B.A., Adeona's Chairman and CEO, stated, "Mr. Eby joins our Scientific Advisory Board at a very exciting time in our Company's history.  We are in the process of planning the commercial launch of wellZin™, our zinc lozenge, that has been developed to reduce the duration and severity of symptoms associated with the common cold. His deep industry knowledge and vast experience in zinc research will provide us with a competitive advantage as we move forward with this program and drive corporate growth for our Company."

About wellZin

In July 2011, Adeona acquired exclusive access to two statistically significant clinical studies that demonstrated a reduction in the duration and severity of symptoms associated with the common cold while taking a particular zinc lozenge. Based on the reduction of common cold symptoms shown in these two clinical studies conducted by Ananda S. Prasad, M.D., Ph.D., Adeona intends to commercialize a similar oral zinc lozenge as a homeopathic over-the-counter drug under the brand name wellZin. Plans for manufacturing, packaging and marketing of wellZin are currently underway. The trademarked name, wellZin, is derived from the combination of "well", as the product seeks to help people suffering from symptoms of the common cold, and "Zin", the root used to distinguish the family brand of zinc products under development by Adeona. wellZin is intended to be marketed for adults in the United States.

About Adeona Pharmaceuticals' Scientific Advisory Board

Members of Adeona's Scientific Advisory Board serve on a continuing basis to advise the Company on scientific and clinical matters related to its programs, as well as recommending and reviewing business opportunities. Mr. Eby joins other industry-leading experts, including: Ashley I. Bush, M.D., Ph.D., a National Health and Medical Research Council Australia Fellow and Head of the Oxidation Disorders Laboratory for the Mental Health Research Institute, University of Melbourne; and, Ananda S. Prasad, M.D., Ph.D., a Distinguished Professor of Internal Medicine at Wayne State University School of Medicine and renowned zinc expert.

About Adeona Pharmaceuticals, Inc.

Adeona is a pharmaceutical company focused on developing innovative medicines for the treatment of serious central nervous system diseases. The Company's strategy is to license product candidates that have demonstrated a certain level of clinical efficacy and develop them to a stage that results in a significant commercial collaboration. Adeona is developing, or has partnered the development of, drug product candidates to treat multiple sclerosis, fibromyalgia, amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. The Company is currently preparing to make the following products commercially available: reaZin™, a prescription medical food for the dietary management of zinc deficiency associated with Alzheimer's disease, and wellZin™, a homeopathic over-the-counter drug for reducing symptoms associated with the common cold. Adeona also operates a wholly owned clinical reference laboratory, Adeona Clinical Laboratory, that provides a broad array of chemistry and microbiology diagnostic tests. For more information, please visit Adeona's website at

This release includes forward-looking statements on Adeona's current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding the commercialization of wellZin and the effectiveness of wellZin. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Adeona's forward-looking statements include, among others, a failure of wellZin to achieve desired results, a failure by us to successfully commercialize wellZin and other factors described in Adeona's report on Form 10-K for the year ended December 31, 2010 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Adeona undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Adeona Announces HartLab Expansion Into Microbiology Testing Services
2. Adeona Completes Equity Financing and Provides Alzheimers Disease Clinical Study Update
3. Adeona Announces Second Quarter 2010 Profitability and Achievements
4. Adeona Announces Five Scientific Publications on Role of Copper Toxicity and Zinc Deficiency in Alzheimers Disease and Cognitive Decline
5. Adeona CEO to Provide Keynote Address at the 2010 MichBio Expo & Conference Emerging Biosciences Showcase
6. Adeona to Hold Annual Shareholder Meeting
7. Adeona Announces Third Quarter 2010 Financial Results and Achievements
8. Adeona Acquires Access to Clinical Data Supporting Oral Zinc for Prevention of Infections in the Elderly
9. Adeona to Present at OneMedForum San Francisco 2011 Conference
10. Adeona to Host Investor Day on Zinc Deficiency in Alzheimers Disease
11. Adeona to Raise $4 Million in Registered Direct Offering
Post Your Comments:
(Date:11/27/2015)... DUBLIN , Nov. 26, 2015 /PRNewswire/ ... announced the addition of the "2016 ... by Test, Country Volume and Sales Segment ... Emerging Opportunities" report to their offering. ... the addition of the "2016 Global ...
(Date:11/26/2015)... , 26 november 2015 ... kondigt de geplande investering aan van ten ... de laboratoria en het mondiale hoofdkantoor in ... uitbreiding zal resulteren in extra kantoorruimte en ... aan de groeiende behoeften van de farmaceutische ...
(Date:11/26/2015)... --> --> Juntendo University ... contrast weighting of MRI for patients with Multiple Sclerosis ... agreement with SyntheticMR in order to use SyMRI in clinical ... to generate multiple contrast images from a single scan and ... making it possible to both fine tune images and recreate ...
Breaking Medicine Technology:
(Date:11/29/2015)... , ... November 29, 2015 , ... Effective immediately, every ... In addition starting on Black Friday Target is offering a “Buy One Scrub Set, ... is a rare opportunity to purchase IguanaMed at a discounted price. , ...
(Date:11/28/2015)... ... 2015 , ... Safe storage for contraceptive devices may not always be easy ... Jersey and the other from Bradley Beach, New Jersey, there is an easy solution ... having to replace NuvaRings more often than necessary. As such, it affords peace of ...
(Date:11/28/2015)... ... November 28, 2015 , ... Pixel Film Studios is back ... to choose from, the possibilities are endless. Users have full control over angle of ... Pulse masking effects, users are sure to get heads to turn. , ProPanel: Pulse ...
(Date:11/27/2015)... Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... study carried out by the University of Toronto and the University of British Columbia ... of hospitalizations for head injuries. The article explains that part of the reason for ...
(Date:11/27/2015)... ... ... A team of Swiss doctors has released a report on mesothelioma relapse ... the findings on the website. Click here to read the details now. ... who were treated with chemotherapy followed by EPP surgery. Among the 106 patients who ...
Breaking Medicine News(10 mins):